Skip to main content
Clinical Trials/CTRI/2025/01/079200
CTRI/2025/01/079200Not yet recruitingPhase 2/3

A Randomized Controlled Clinical study of Shunthi Bidalak in Simple Allergic Conjunctivitis

Dr Mayur Nakade1 site in 1 country56 target enrollmentStarted: February 1, 2025Last updated:

Trial Snapshot

Phase
Phase 2/3
Status
Not yet recruiting
Sponsor
Enrollment
56
Locations
1
Primary Endpoint
Reduction of Itching.

Study Overview

Brief Summary

This study is a randomized controlled , open label , parallel group study on efficacy of Shunthi Bidalak in

Simple Allergic Conjunctivitis for 14 days in 30 patients with simple allergic conjunctivitis that will be conducted in Bharati Vidyapeeth (Deemed to be University), College of Ayurved and Hospital, Department of Shalakya Tantra, OPD number 24, Katraj, Dhankawadi, Pune

  1. The primary outcome measures will be Reduction of Itching,Burning sensation,Redness,Photophobia and Lacrimation.

Study Design

Study Type
Interventional
Allocation
Other
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 60.00 Year(s) (—)

Inclusion Criteria

  • Participants suffering from Simple Allergic Conjunctivitis.
  • 1 Age 18 to 60 years 2 Gender Both male and female.

Exclusion Criteria

  • 1 Participants suffering from ocular surface pathology.
  • 2 post-operative participants.
  • 3 Participants suffering from all other type of conjunctivitis.

Outcomes

Primary Outcomes

Reduction of Itching.

Time Frame: 14 days

Reduction of Burning sensation.

Time Frame: 14 days

Reduction of Redness.

Time Frame: 14 days

Reduction of Photophobia.

Time Frame: 14 days

Reduction of Lacrimation.

Time Frame: 14 days

Secondary Outcomes

  • Relief From Signs And Symptoms(1 year)

Investigators

Sponsor
Dr Mayur Nakade
Sponsor Class
Other [self]
Responsible Party
Principal Investigator
Principal Investigator

Dr Mayur Nakade

Bharati Vidyapeeth (Deemed To be University ) , College of Ayurveda, Pune-43

Study Sites (1)

Loading locations...

Similar Trials